GLP-1 Peptide Atlas, by Delfa

CompletedPhase 3Results posted

Liraglutide in Adolescents With Type 1 Diabetes

Effect of Liraglutide on Glycemic Control, Glucagon Secretion and Inflammatory Markers in Adolescents With Type 1 Diabetes Mellitus

Lead sponsor

University at Buffalo

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 1 diabetes

Key I/E criterion

•HbA1c ≤10%

Primary endpoint

•Mean Weekly Blood Glucose

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02516657

Org study ID437619-6

Timeline

Milestones

Study first posted2015-08-06estimated

Primary completion2022-08-03actual

Study completion2023-08-03actual

Last update posted2025-04-20actual

Results first posted2025-04-20actual

Study start2012-05actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age15 Years

Maximum age21 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of Type 1 Diabetes Mellitus greater than 1 year

•Insulin regimen - continuous subcutaneous insulin infusion with continuous glucose monitoring device

•HbA1c <10%

Exclusion criteria

•Previous exposure to liraglutide

•History of abdominal surgery

•Gastrointestinal reflux disease

•History of acute or chronic pancreatitis

•History of alcohol abuse or unwillingness to abstain from alcohol during the study

•History of thyroid cancer

•Family history of Multiple Endocrine Neoplasia 2B syndrome

•Pregnant/breastfeeding females

•Individuals with antibody-negative insulin requiring diabetes that is consistent with Monogenic Diabetes of Youth

•Individuals with steroid induced or cystic fibrosis related diabetes

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Safety / tolerability / PK

Glycemic / diabetes

4 endpoints

Primary/registry result

Mean Weekly Blood Glucose

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

change from baseline, improvement

Posted result

Group	Value (mean), mg/dL	95% CI
Liraglutide 0.6 mgVisit 1, before liraglutide	187	—
Visit 2, after liraglutide	178	—

Primary/protocol endpoint

Mean Weekly Blood Glucose

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

change from baseline, improvement

Secondary/registry result

Total Daily Insulin Dose

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

change from baseline, improvement

Posted result

Group	Value (mean), U/kg/day	95% CI
Before Liraglutide	0.97	—
Liraglutide Treatment	0.67	—

Secondary/protocol endpoint

Total Daily Insulin Dose

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

change from baseline, improvement

Safety / tolerability / PK

4 endpoints

Other/protocol endpoint

Blood Sugar < 70 mg/dL

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

Documented hypoglycemia

event count, event

Other/protocol endpoint

Serum Amylase Level

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

change from baseline, descriptive

Other_pre_specified/registry result

Blood Sugar < 70 mg/dL

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

Documented hypoglycemia

event count, event

Posted result

Group	Value (mean), episodes	95% CI
Before Liraglutide	5.5	—
Liraglutide Treatment	3.3	—

Other_pre_specified/registry result

Serum Amylase Level

Time frame:Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7;

change from baseline, descriptive

Posted result

Group	Value (mean), U/L	95% CI
Before Liraglutide	36	—
Liraglutide Treatment	33	—

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.